What is the next earnings date for IDRA stock?
IDERA PHARMACEUTICALS INC (IDRA) will report earnings on 2023-03-29.
IDERA PHARMACEUTICALS INC (IDRA) Forecast, Price Target & Analyst Ratings
NASDAQ:IDRA • US45168K4058
Current stock price
0.425 USD
-0.12 (-21.57%)
At close:
0.42 USD
-0.01 (-1.18%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IDERA PHARMACEUTICALS INC (IDRA).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
$0.00
Upside
-100.00%
From current price of $0.43 to mean target of $0.00, Based on 6 analyst forecasts
Low
$0.00
Median
$0.00
High
$0.00
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
IDRA was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about IDRA.
In the previous month the buy percentage consensus was at a similar level.
IDRA was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-03-19 | JMP Securities | Downgrade | Outperform -> Market Perform |
| 2021-03-19 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2021-03-19 | Wedbush | Downgrade | Outperform -> Neutral |
| 2021-03-19 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-03-19 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 29, 2023
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2017 | 2018 | 2019 | 2020 | 2021 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 900K -94.44% | 660K -26.67% | 1.45M 119.70% | -100.00% | ||
| EBITDA YoY % growth | -65.72M -72.49% | -56.17M 14.53% | -45.77M 18.52% | -36.72M 19.97% | N/A 28.12% | |
| EBIT YoY % growth | -66.47M -71.49% | -56.6M 14.85% | -45.89M 18.92% | -37.285M 20.05% | -28.724M 28.18% | |
| Operating Margin | -7,385.56% | -8,575.76% | -3,164.83% | N/A | N/A | |
| EPS YoY % growth | -3.36 -35.48% | -2.27 32.44% | -2.94 -29.52% | -1.33 -30.95% | -1.88 160.78% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
IDERA PHARMACEUTICALS INC / IDRA Forecast FAQ
What is the number of analysts for IDRA stock?
The number of analysts covering IDERA PHARMACEUTICALS INC (IDRA) is 6.